Department of Pharmacology, Nirma University, Ahmedabad, Gujarat, India.
Indian J Pharmacol. 2017 Jan-Feb;49(1):4-9. doi: 10.4103/0253-7613.201037.
Stroke and traumatic brain injury (TBI) are the critical public health and socioeconomic problems throughout the world. At present, citicoline is used as a coadjuvant for the management of acute ischemic stroke (AIS) and TBI in various countries. This systemic review analyzes the beneficial role of citicoline in AIS and TBI. This systemic review is based on "PubMed" and "Science Direct" search results for citicoline role in stroke and TBI. In this systemic review, we included 12 human trials. A meta-analysis was performed on the basis of neurological evaluation, functional evaluation and Glasgow outcome scale, domestic adaptation evaluation outcomes, and cognitive outcome individually. In neurological evaluation, domestic adaptation evaluation, and cognitive outcomes, there was no significant difference in both the citicoline and placebo groups (odds ratio [OR] = 1.04 [0.9-1.2, = 0.583]; OR = 1.1 [0.94-1.27, = 0.209]; OR = 0.953 [0.75-1.2, = 0.691]). In evaluation of functional outcomes, there was significant difference in both groups and OR was 1.18 (1.04-1.34, = 0.01). Functional outcomes were significantly improved by citicoline, but the positive role of this drug in neurological recovery, domestic adaptation, and cognitive outcomes is still a topic of discussion for future.
中风和创伤性脑损伤（TBI）是全球范围内严重的公共卫生和社会经济问题。目前，胞磷胆碱在各国被用作急性缺血性中风（AIS）和 TBI 的辅助治疗药物。本系统评价分析了胞磷胆碱在 AIS 和 TBI 中的有益作用。本系统评价基于“PubMed”和“Science Direct”对胞磷胆碱在中风和 TBI 中作用的搜索结果。在本系统评价中，我们纳入了 12 项人类试验。分别对神经功能评估、功能评估和格拉斯哥结局量表、国内适应评估结果和认知结果进行了荟萃分析。在神经功能评估、国内适应评估和认知结果方面，胞磷胆碱组和安慰剂组之间没有显著差异（比值比 [OR] = 1.04 [0.9-1.2， = 0.583]；OR = 1.1 [0.94-1.27， = 0.209]；OR = 0.953 [0.75-1.2， = 0.691]）。在功能评估方面，两组之间存在显著差异，OR 为 1.18（1.04-1.34， = 0.01）。胞磷胆碱可显著改善功能结局，但该药在神经恢复、国内适应和认知结局方面的积极作用仍有待进一步讨论。
